Exenatide (a GLP-1 agonist) expresses anti-inflammatory properties in cultured human monocytes/macrophages in a protein kinase A and B/Akt manner

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Pharmacological Reports

• Publication date

  2016-03-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.pharep.2015.10.008PMID 26922535
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effects of incretin agonists on endothelial nitric oxide synthase expression and nitric oxide synthesis in human coronary artery endothelial cells exposed to TNFα and glycated albumin

  2015cited by this paper
• Exenatide (a GLP-1 agonist) improves the antioxidative potential of in vitro cultured human monocytes/macrophages

  2015cited by this paper
• Involvement of IGF-1 and Akt in M1/M2 activation state in bone marrow-derived macrophages.

  2015cited by this paper
• Liraglutide attenuates high glucose-induced abnormal cell migration, proliferation, and apoptosis of vascular smooth muscle cells by activating the GLP-1 receptor, and inhibiting ERK1/2 and PI3K/Akt signaling pathways

  2015cited by this paper
• Exendin-4 Promotes Beta Cell Proliferation via PI3k/Akt Signalling Pathway

  2015cited by this paper
• Exenatide protects against hypoxia/reoxygenation-induced apoptosis by improving mitochondrial function in H9c2 cells

  2014cited by this paper
• Macrophage phenotypes in atherosclerosis

  2014cited by this paper
• Exendin‐4 decreases liver inflammation and atherosclerosis development simultaneously by reducing macrophage infiltration

  2014cited by this paper
• Comparison of chosen activation markers of human monocytes/macrophages isolated from the peripheral blood of young and elderly volunteers

  2014cited by this paper
• Eplerenone mimics features of the alternative activation in macrophages obtained from patients with heart failure and healthy volunteers.

  2014cited by this paper
• Metformin affects macrophages’ phenotype and improves the activity of glutathione peroxidase, superoxide dismutase, catalase and decreases malondialdehyde concentration in a partially AMPK-independent manner in LPS-stimulated human monocytes/macrophages

  2014cited by this paper
• Exendin-4 Reduces Ischemic Brain Injury in Normal and Aged Type 2 Diabetic Mice and Promotes Microglial M2 Polarization

  2014cited by this paper
• Selective Inhibition of PI3K/Akt/mTOR Signaling Pathway Regulates Autophagy of Macrophage and Vulnerability of Atherosclerotic Plaque

  2014cited by this paper
• Anti‐inflammatory effects of exendin‐4, a glucagon‐like peptide‐1 analog, on human peripheral lymphocytes in patients with type 2 diabetes

  2013cited by this paper
• Exendin‐4 inhibits iNOS expression at the protein level in LPS‐stimulated Raw264.7 macrophage by the activation of cAMP/PKA pathway

  2013cited by this paper
• Exendin-4 protects endothelial cells from lipoapoptosis by PKA, PI3K, eNOS, p38 MAPK, and JNK pathways.

  2013influential reference
• Glucagon-like peptide-1 inhibits adipose tissue macrophage infiltration and inflammation in an obese mouse model of diabetes

  2012cited by this paper
• Glucagon-like peptide-1 (GLP-1) induces M2 polarization of human macrophages via STAT3 activation.

  2012cited by this paper
• Oxidative stress and macrophage foam cell formation during diabetes mellitus-induced atherogenesis: role of insulin therapy.

  2012cited by this paper
• A GLP-1 receptor agonist liraglutide inhibits endothelial cell dysfunction and vascular adhesion molecule expression in an ApoE-/- mouse model

  2011cited by this paper
• Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes

  2011cited by this paper
• Native incretins prevent the development of atherosclerotic lesions in apolipoprotein E knockout mice

  2011cited by this paper
• Inhibition of Monocyte Adhesion to Endothelial Cells and Attenuation of Atherosclerotic Lesion by a Glucagon-like Peptide-1 Receptor Agonist, Exendin-4

  2010cited by this paper
• Alternative activation of macrophages: immune function and cellular biology.

  2009cited by this paper
• Exendin‐4 Therapy in NOD Mice with New‐Onset Diabetes Increases Regulatory T Cell Frequency

  2008cited by this paper
• Direct apoptotic effects of free fatty acids on human endothelial cells.

  2008cited by this paper
• Monocyte and macrophage heterogeneity

  2005influential reference
• Monocyte Release of Tumor Necrosis Factor-α and Interleukin-1β in Primary Type IIa and IIb Dyslipidemic Patients Treated With Statins or Fibrates

  2005cited by this paper
• Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes.

  2004cited by this paper
• Minireview: Glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system.

  2004cited by this paper
• EMBOSS: the European Molecular Biology Open Software Suite.

  2000cited by this paper
• Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications.

  1979cited by this paper
• A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

  1976cited by this paper

• The association between glucagon-like peptide 1 receptor agonists therapy and outcomes after heart transplant.

  2026cites this paper
• THE CRITICAL ROLE OF INFLAMMATION IN ATHEROSCLEROTIC CORONARY ARTERY HEART DISEASE.

  2026cites this paper
• All-cause mortality and cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes and heart failure with reduced ejection fraction

  2025cites this paper
• Current Perspectives on GLP-1 Agonists in Contemporary Clinical Practice from Science and Mechanistic Foundations To Optimal Translation

  2025cites this paper
• Exploring the Role of GLP‐1 Agents in Managing Diabetic Foot Ulcers: A Narrative and Systematic Review

  2025influential citation
• GLP-1 receptor agonists in IBD: exploring the crossroads of metabolism and inflammation

  2025cites this paper
• Effect of the GLP‐1 receptor agonist exenatide on pro‐inflammatory and metabolic biomarkers in individuals with alcohol use disorder: Post hoc results from a randomized, double‐blinded, placebo‐controlled clinical trial

  2025cites this paper
• Glucagon-Like Peptide-1 Is Prognostic of Mortality in Acute Respiratory Failure

  2025cites this paper
• GLP-1 as a regulator of sepsis outcomes: Insights into cellular metabolism, inflammation, and therapeutic potential.

  2025cites this paper
• Epicardial Adipose Tissue As Target of the Incretin-Based Therapies in Cardio-Metabolic Pathologies: A Narrative Review.

  2025cites this paper
• Unveiling Gestational Diabetes: An Overview of Pathophysiology and Management

  2025cites this paper
• State of the Art Review: Glucagon-Like Peptide-1 in Obesity-Related Asthma

  2025cites this paper
• The GLP-1 receptor agonist exenatide improves recovery from spinal cord injury by inducing macrophage polarization toward the M2 phenotype

  2024cites this paper
• Recent advances in incretin-based therapy for MASLD: from single to dual or triple incretin receptor agonists

  2024cites this paper
• Liraglutide Therapy in Obese Patients Alters Macrophage Phenotype and Decreases Their Tumor Necrosis Factor Alpha Release and Oxidative Stress Markers—A Pilot Study

  2024cites this paper
• Effect of glucagon-like peptide-1 receptor agonists on prostate cancer: A review

  2024cites this paper
• Inflammatory proteins associated with Alzheimer’s disease reduced by a GLP1 receptor agonist: a post hoc analysis of the EXSCEL randomized placebo controlled trial

  2024cites this paper
• Exploring the clinical effectiveness of glucagon-like peptide-1 receptor agonists in managing cardiovascular complications: an updated comprehensive review and future directives

  2024cites this paper
• Assessing the therapeutic potential of long-chain isomaltooligosaccharides in diabetic and hyperlipidemic rats

  2024cites this paper
• Can glucagon-like peptide-1 receptor agonists induce asthma? An analysis of the FAERS database

  2024cites this paper
• Cytotoxicity and anti-inflammatory properties of a GLP-1 receptor agonist in a model of human peripheral blood mononuclear cell culture

  2024influential citation
• Liraglutide Attenuates Diabetic Cardiomyopathy via the ILK/PI3K/AKT/PTEN Signaling Pathway in Rats with Streptozotocin-Induced Type 2 Diabetes Mellitus

  2024cites this paper
• The Role of Glucagon-Like Peptide-1 Receptor Agonists in Chronic Obstructive Pulmonary Disease

  2023cites this paper
• The benefits of GLP1 receptors in cardiovascular diseases

  2023cites this paper
• Liraglutide Pretreatment Attenuates Sepsis-Induced Acute Lung Injury.

  2023cites this paper
• The anti-inflammatory and immunological properties of GLP-1 Receptor Agonists.

  2022cites this paper
• Exenatide improves antioxidant capacity and reduces the expression of LDL receptors and PCSK9 in human insulin-secreting 1.1E7 cell line subjected to hyperglycemia and oxidative stress

  2022cites this paper
• GLP-1 and GLP-2 Orchestrate Intestine Integrity, Gut Microbiota, and Immune System Crosstalk

  2022cites this paper
• Targeting Persistent Neuroinflammation after Hypoxic-Ischemic Encephalopathy—Is Exendin-4 the Answer?

  2022cites this paper
• The role of protein kinases as key drivers of metabolic dysfunction-associated fatty liver disease progression: New insights and future directions.

  2022cites this paper
• Exenatide improves antioxidant capacity and reduces the expression of LDL receptors and PCSK9 in human insulin-secreting 1.1E7 cell line subjected to hyperglycemia and oxidative stress

  2022cites this paper
• Characterization of the SARS‐CoV‐2 E Protein: Sequence, Structure, Viroporin, and Inhibitors

  2021cites this paper
• Liraglutide Increases the Catabolism of Apolipoprotein B100–Containing Lipoproteins in Patients With Type 2 Diabetes and Reduces Proprotein Convertase Subtilisin/Kexin Type 9 Expression

  2021cites this paper
• Long non-coding RNA THRIL inhibits miRNA-24-3p to upregulate neuropilin-1 to aggravate cerebral ischemia-reperfusion injury through regulating the nuclear factor κB p65 signaling

  2021cites this paper
• Metabolic Hormones Modulate Macrophage Inflammatory Responses

  2021cites this paper
• Analysis of N15-rat growth hormone after incubation with rat subcutaneous tissue and immune cells using ultra-pressure chromatography-mass spectrometry.

  2021cites this paper
• Rationale for and Design of the Study of Early Enteral Dextrose in Sepsis: A Pilot Placebo-Controlled Randomized Clinical Trial.

  2020cites this paper
• Rationale for and Design of the Study of Early Enteral Dextrose in Sepsis (SEEDS): A Pilot Placebo-Controlled Randomized Clinical Trial

  2020cites this paper
• Nutraceuticals Targeting Generation and Oxidant Activity of Peroxynitrite May Aid Prevention and Control of Parkinson’s Disease

  2020cites this paper
• Effect of hCMSCs and liraglutide combination in ALI through cAMP/PKAc/β-catenin signaling pathway

  2020cites this paper
• Proinflammatory biomarkers are associated with prediabetes in patients with schizophrenia

  2020cites this paper
• Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence

  2020cites this paper
• Antidiabetes Agents against Sars-Cov-2 Infection

  2020cites this paper
• Pharmacological Signatures of the Exenatide Nanoparticles Against Hepatic Ischemia/Reperfusion-induced Pancreatic Injury.

  2019cites this paper
• The impact of exenatide (a GLP-1 agonist) on markers of inflammation and oxidative stress in normal human astrocytes subjected to various glycemic conditions.

  2019cites this paper
• Incretin Hormones in the Control of Immunometabolism

  2019cites this paper
• Therapeutic Effects of Endogenous Incretin Hormones and Exogenous Incretin-Based Medications in Sepsis.

  2019cites this paper
• Anti-inflammatory properties of antidiabetic agents

  2019cites this paper
• Inulin-type fructan improves diabetic phenotype and gut microbiota profiles in rats

  2018cites this paper
• Inflammageing and metaflammation: The yin and yang of type 2 diabetes.

  2018cites this paper
• اثر اگزندین 4 بر فعالیت حیاتی، تولید نیتریک اکساید وTNF-α در کشت ماکروفاژ صفاقی موش C57BL/6

  2018cites this paper
• Multiple target tissue effects of GLP-1 analogues on non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).

  2018cites this paper
• Oleoylethanolamide alleviates macrophage formation via AMPK/PPARα/STAT3 pathway

  2018cites this paper
• Inflammation-Induced Adverse Pregnancy and Neonatal Outcomes Can Be Improved by the Immunomodulatory Peptide Exendin-4

  2018cites this paper
• GLP-1 Receptor Agonists and Cardiovascular Disease: a Meta-Analysis of Recent Cardiac Outcome Trials

  2018cites this paper
• High‐density lipoprotein immunomodulates the functional activities of macrophage and cytokines produced during ex vivo macrophage‐CD4+ T cell crosstalk at the recent‐onset human type 1 diabetes

  2017cites this paper
• Erratum to “Exenatide (a GLP-1 agonist) expresses anti-inflammatory properties in cultured human monocytes/macrophages in a protein kinase A and B/Akt manner”

  2017cites this paper
• Autocrine Interleukin-10 Mediates Glucagon-Like Peptide-1 Receptor-Induced Spinal Microglial β-Endorphin Expression

  2017cites this paper
• اثر اگزندین 4 بر فعالیت حیاتی، تولید نیتریک اکساید وTNF-α در کشت ماکروفاژ صفاقی موش C57BL/6

  2017cites this paper
• Hypothèses mécanistiques pouvant expliquer les effets cardiovasculaires observés avec les inhibiteurs de SGLT2 et les agonistes des récepteurs du GLP-1

  2017cites this paper
• Exendin-4 Exhibits Enhanced Anti-tumor Effects in Diabetic Mice

  2017cites this paper
• Both classic Gs-cAMP/PKA/CREB and alternative Gs-cAMP/PKA/p38β/CREB signal pathways mediate exenatide-stimulated expression of M2 microglial markers.

  2017cites this paper
• Combination of exendin-4 and DPP-4 silencing promoted angiogenesis of human coronary artery endothelial cells via activation of PI3K/Akt pathway.

  2017cites this paper
• Type 2 diabetes and cardiovascular disease: A metabolic overview of recent clinical trials.

  2017cites this paper
• After the LEADER trial and SUSTAIN-6, how do we explain the cardiovascular benefits of some GLP-1 receptor agonists?

  2017cites this paper
• Novel cardioprotective and regenerative therapies in acute myocardial infarction: a review of recent and ongoing clinical trials

  2016cites this paper
• Glucagon-like peptide 1 improves insulin resistance in vitro through anti-inflammation of macrophages

  2016cites this paper
• Exenatide and metformin express their anti-inflammatory effects on human monocytes/macrophages by the attenuation of MAPKs and NFκB signaling

  2016cites this paper
• The Cardiovascular Biology of Glucagon-like Peptide-1.

  2016cites this paper